Pomerantz Law Firm Launches Class Action Against SelectQuote, Inc. Amid Securities Fraud Allegations
On September 28, 2025, Pomerantz LLP announced the initiation of a class action lawsuit against SelectQuote, Inc., a company listed on the NYSE under the ticker symbol SLQT. This legal action comes after concerns that SelectQuote, along with some of its executives and board members, may have engaged in fraudulent practices affecting their securities. Investors who suffered losses related to their investment in SelectQuote are being urged to reach out to Pomerantz to discuss possible participation in the lawsuit. Interested parties can contact Danielle Peyton via email or phone, providing necessary information such as mailing address, phone number, and the number of shares purchased.
The lawsuit is primarily focused on allegations of securities fraud, which claim that the company and its leadership may have misled investors about the organization's business practices and financial performance. The allegations were further substantiated by recent findings from the U.S. Department of Justice (DOJ), which filed a complaint against SelectQuote accusing the firm of receiving substantial illegal kickbacks from health insurance companies between the years 2016 and 2021. The DOJ asserts that SelectQuote had directed Medicare beneficiaries towards health plans that were financially lucrative for the company, all while misleading clients about the objectivity of the coverage they were offering, branding it as 'unbiased'.
In light of these serious allegations, SelectQuote’s stock price plummeted significantly, dropping 19.24% to close at $2.56 per share on the same day the DOJ’s findings were made public. This decline reflects the turmoil and uncertainty surrounding SelectQuote's business practices and casts a long shadow over the company’s reputation within the market.
Pomerantz LLP has a long-standing history of handling complex corporate litigation, particularly in the realms of securities fraud and class action suits. The firm was founded by Abraham L. Pomerantz, often referred to as the 'dean of the class action bar'. With decades of expertise in advocating for the rights of defrauded investors, Pomerantz stands at the forefront of legal battles against corporate misconduct, having achieved vast settlements for those affected.
Investors with ties to SelectQuote must act quickly if they wish to participate in the class action, as the deadline to apply as a Lead Plaintiff is set for October 10, 2025. This legal journey raises significant concerns not only for the future of SelectQuote but also for the ongoing regulatory landscape regarding corporate governance in the healthcare sector.
As the case progresses, all eyes will be on how SelectQuote navigates these serious allegations and what precedents this lawsuit may set for the industry. The allegations, if validated, could usher in waves of legal scrutiny for other players in the market who may be implicated in similar practices. Investors are encouraged to keep abreast of developments as the case unfolds, as the implications could be far-reaching for stakeholders in the company and beyond.
The lawsuit is primarily focused on allegations of securities fraud, which claim that the company and its leadership may have misled investors about the organization's business practices and financial performance. The allegations were further substantiated by recent findings from the U.S. Department of Justice (DOJ), which filed a complaint against SelectQuote accusing the firm of receiving substantial illegal kickbacks from health insurance companies between the years 2016 and 2021. The DOJ asserts that SelectQuote had directed Medicare beneficiaries towards health plans that were financially lucrative for the company, all while misleading clients about the objectivity of the coverage they were offering, branding it as 'unbiased'.
In light of these serious allegations, SelectQuote’s stock price plummeted significantly, dropping 19.24% to close at $2.56 per share on the same day the DOJ’s findings were made public. This decline reflects the turmoil and uncertainty surrounding SelectQuote's business practices and casts a long shadow over the company’s reputation within the market.
Pomerantz LLP has a long-standing history of handling complex corporate litigation, particularly in the realms of securities fraud and class action suits. The firm was founded by Abraham L. Pomerantz, often referred to as the 'dean of the class action bar'. With decades of expertise in advocating for the rights of defrauded investors, Pomerantz stands at the forefront of legal battles against corporate misconduct, having achieved vast settlements for those affected.
Investors with ties to SelectQuote must act quickly if they wish to participate in the class action, as the deadline to apply as a Lead Plaintiff is set for October 10, 2025. This legal journey raises significant concerns not only for the future of SelectQuote but also for the ongoing regulatory landscape regarding corporate governance in the healthcare sector.
As the case progresses, all eyes will be on how SelectQuote navigates these serious allegations and what precedents this lawsuit may set for the industry. The allegations, if validated, could usher in waves of legal scrutiny for other players in the market who may be implicated in similar practices. Investors are encouraged to keep abreast of developments as the case unfolds, as the implications could be far-reaching for stakeholders in the company and beyond.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.